Share This Page
Drug Price Trends for COREG CR
✉ Email this page to a colleague
Best Wholesale Price for COREG CR
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Unit | Dates | Price Type |
|---|---|---|---|---|---|---|---|---|
| COREG CR EXTENDED RELEASE CAP 20MG | Woodward Pharma Services LLC | 69784-0385-13 | 30 | 43.70 | 1.45667 | EACH | 2024-03-15 - 2025-09-01 | FSS |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Unit | >Dates | >Price Type |
Market Analysis and Price Projections for COREG CR
Introduction to COREG CR
COREG CR, also known as carvedilol, is a non-cardioselective beta blocker used to treat various cardiovascular conditions, including high blood pressure, heart failure, angina, and atrial fibrillation. It is available in both immediate-release (IR) and extended-release (CR) formulations[2][5].
Market Overview
The global carvedilol drug market, which includes COREG CR, is poised for significant growth driven by the increasing prevalence of cardiovascular diseases (CVDs) and hypertension worldwide.
- Global Prevalence of CVDs: According to the World Health Organization (WHO), CVDs are the leading cause of death globally, accounting for 17.9 million deaths annually. Hypertension affects over 1.13 billion people worldwide, with one in four men and one in five women suffering from this condition[3][4].
Market Drivers
Several factors are driving the growth of the carvedilol market:
-
Increasing Incidence of Cardiovascular Diseases: The rising incidence of heart failure, high blood pressure, and other cardiovascular conditions is a major driver. For instance, heart disease claims one life in the United States every 34 seconds, and it was the cause of nearly 697,000 deaths in 2020[3][4].
-
Growing Healthcare Infrastructure: The expansion of healthcare infrastructure, particularly in regions like Asia Pacific and North America, is expected to boost market growth. The increasing investment in research and development (R&D) and the presence of key market players in these regions are also significant factors[3][4].
-
High Mortality and Economic Burden: The economic burden of treating and managing CVDs is substantial. For example, heart disease costs the United States around $229 billion annually, which includes the cost of prescription drugs, healthcare services, and lost income from deaths[3].
Segmentation of the Market
The global carvedilol drug market is segmented in several ways:
-
By Application: The market is segmented into high blood pressure, congestive heart failure (CHF), ventricular dysfunction, and others. The CHF segment is expected to hold a substantial market share due to the increasing prevalence of CHF globally[3][4].
-
By Distribution Channel: The hospital segment is anticipated to hold a noteworthy market share due to the rising prevalence of CVDs and hypertension, and the preference for treatment by highly skilled medical personnel in hospital settings[3].
-
By Geography: The Asia Pacific region is expected to witness significant growth due to the increasing prevalence of hypertension and CVDs in low and middle-income countries. North America is anticipated to gain the largest market share due to the high prevalence of heart-related diseases and the presence of efficient healthcare infrastructure[3][4].
Price Analysis of COREG CR
The prices of COREG CR vary based on the dosage and the pharmacy:
-
Extended Release Capsules:
- 10 mg: Prices range from $859.58 to $1,964.68 for a 30-capsule supply.
- 20 mg: Prices range from $859.58 to $1,964.68 for a 30-capsule supply.
- 40 mg: Prices range from $356.73 to $1,964.68 for a 30-capsule supply.
- 80 mg: Prices range from $859.58 to $1,964.68 for a 30-capsule supply[2].
-
Generic Versions: Generic versions of COREG CR are available at significantly lower prices, such as $108.60 for a 30-capsule supply of carvedilol 40 mg extended-release capsules[2].
Impact of Generic Versions
The approval of generic versions of COREG has significantly impacted the market:
-
Competition: The FDA's approval of 14 generic versions of the immediate-release formulation of Coreg dealt a substantial blow to GlaxoSmithKline (GSK) and its partner, Flamel Technologies. This increased competition is expected to drive down prices and affect market share[1].
-
Patient Compliance: A study questioning the compliance benefits of the once-daily CR version compared to the immediate-release version has further complicated the market dynamics. Doctors may prefer prescribing generic versions of the IR formulation, which could impact the sales of COREG CR[1].
Price Projections
Given the market drivers and the impact of generic versions, here are some price projection insights:
-
Short-Term: Prices for COREG CR are likely to remain competitive due to the presence of generic alternatives. Patients and healthcare providers may opt for the more affordable generic versions, which could lead to a slight decrease in the prices of the branded product[2].
-
Long-Term: The overall market for carvedilol is expected to grow, driven by the increasing prevalence of CVDs and hypertension. However, the branded COREG CR may face continued pressure from generic competitors, potentially stabilizing or slightly reducing prices over the long term[3][4].
Key Takeaways
- The global carvedilol drug market, including COREG CR, is growing due to the rising incidence of cardiovascular diseases and hypertension.
- The market is segmented by application, distribution channel, and geography, with the CHF segment and hospital distribution channel expected to be significant.
- Generic versions of COREG CR are available and are likely to impact the pricing and market share of the branded product.
- Long-term growth is anticipated, but prices may remain competitive due to generic competition.
FAQs
Q: What conditions is COREG CR used to treat? A: COREG CR is used to treat high blood pressure, heart failure, angina, and atrial fibrillation.
Q: How does the approval of generic versions affect COREG CR? A: The approval of generic versions increases competition, potentially driving down prices and affecting the market share of the branded product.
Q: What are the key drivers of the global carvedilol drug market? A: The key drivers include the increasing prevalence of cardiovascular diseases, growing healthcare infrastructure, and high mortality and economic burden associated with CVDs.
Q: Which region is expected to witness the most significant growth in the carvedilol market? A: The Asia Pacific region is expected to witness significant growth due to the increasing prevalence of hypertension and CVDs in low and middle-income countries.
Q: How do prices vary for different dosages of COREG CR? A: Prices vary significantly based on the dosage, with the 40 mg extended-release capsules being one of the more affordable options compared to higher dosages.
Cited Sources
- SP Global Market Intelligence - FDA Approves First Generic Versions of GSK's Cardiovascular Drug...
- Drugs.com - Coreg CR Prices, Coupons, Copay Cards & Patient Assistance
- GlobeNewswire - Global Carvedilol Drug Market to Grow at a Significant CAGR During 2022-2031
- Research Nester - Carvedilol Drug Market Size, Growth Forecasts 2037
- Drugs.com - Coreg Prices, Coupons, Copay Cards & Patient Assistance
More… ↓
